Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
Nuwellis has announced the issuance of a new patent for its pediatric continuous renal replacement therapy (CRRT) device, Vivian™, from the USPTO. The patent includes innovations such as self-centering fluid bag hangers, density compensation mechanisms, and self-sealing access ports, enhancing fluid management accuracy, ease of use, and system reliability. Vivian™'s new features streamline dialysis modes and secure seals, reducing leak risks. This is the second of several patents for Vivian™, underscoring Nuwellis' dedication to improving treatment for critically ill children. Nestor Jaramillo, President and CEO, highlighted this development as a significant milestone in pediatric CRRT.
- Grant of a new patent from the USPTO for Vivian™.
- Innovations include self-centering fluid bag hangers, density compensation mechanisms, and self-sealing access ports.
- Enhanced accuracy in fluid management.
- Increased ease of use and reliability.
- Reduces risk of leaks with temperature-adjusting auto-clamp.
- Second of several upcoming patents, indicating ongoing product development.
- None.
Insights
Nuwellis' new patent for their pediatric continuous renal replacement therapy (CRRT) device, Vivian™, demonstrates a significant stride in medical technology specifically targeting fluid overload in children. This patent's emphasis on innovative features like self-centering fluid bag hangers and density compensation mechanisms reflects substantial advancements in fluid management accuracy. These improvements are not merely technical upgrades but also address critical clinical necessities. For pediatric patients, precise fluid management is important and these innovations could minimize potential complications associated with CRRT.
Another key improvement includes the self-sealing access ports, simplifying the configuration of various dialysis modes. This feature is particularly beneficial in clinical settings where ease of use can directly impact the efficiency and effectiveness of treatments. Additionally, the introduction of temperature-adjusting auto-clamps to prevent leaks underscores a significant step towards enhancing system reliability, which is paramount in critical care environments.
For investors, these advancements signify Nuwellis' commitment to innovation and its potential to strengthen market position in pediatric nephrology. However, it is essential to monitor subsequent patents and integration of these technologies into clinical practice to fully grasp their market impact.
This patent could potentially bolster Nuwellis' positioning within the pediatric medical device market. By securing patents that address practical issues such as ease of use and reliability, Nuwellis is strategically differentiating itself from competitors. In terms of market perception, the announcement may enhance investor confidence in Nuwellis' long-term growth strategy.
However, the market impact of this patent will also depend on the time it takes for these innovations to transition from the patent stage to widespread clinical use and adoption. Historical data suggests that new medical technologies often face extensive regulatory scrutiny and gradual adoption rates. Therefore, while this patent is a positive development, it's vital to consider the timeline for its potential revenue generation and market penetration.
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent grant of a new patent from the United States Patent and Trademark Office (USPTO) related to its groundbreaking pediatric continuous renal replacement therapy (CRRT), Vivian™. This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This is the second of several forthcoming patents for Vivian, underscoring Nuwellis’ commitment to development of novel technology designed to improve treatment options for critically ill children.
The patent claims, include self-centering fluid bag hangers and density compensation mechanisms for enhanced accuracy in fluid management. Ease of use is increased with self-sealing access ports for easy configuration of various dialysis modes, streamlining the treatment process. Additionally, reliability is boosted by a temperature-adjusting auto-clamp that ensures secure seals, reducing the risk of leaks and enhancing overall system dependability.
"We are thrilled to announce the issuance of this patent, which represents a significant milestone in the development of our pediatric continuous renal replacement therapy, Vivian," said Nestor Jaramillo, President and Chief Executive Officer at Nuwellis. "These innovations not only reinforce our position as a leader in fluid management solutions but also highlight our dedication to advancing technology that can make a real difference in the lives of thousands of pediatric patients across the U.S. Our focus on increased accuracy, ease of use, and reliability will help ensure that children receiving critical care have access to the best possible treatment options."
About Vivian
Nuwellis is currently developing Vivian, a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children with limited or no kidney function. Vivian is not yet cleared by the FDA. This development effort was funded in part by a
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
CONTACTS
Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
FAQ
What new patent did Nuwellis receive for NUWE?
What innovations are included in the new patent for Vivian™ by NUWE?
How does the new patent improve NUWE's Vivian™?
Why is the new patent for Vivian™ significant for NUWE?
How many patents has Nuwellis secured for Vivian™?
